Innoviva (NASDAQ: INVA)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-07-27 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.440 | 0.390 | -0.0500 | ||||
REV | 90.500M | 90.059M | -441.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Innoviva (NASDAQ: INVA) through any online brokerage.
Other companies in Innoviva’s space includes: Theravance Biopharma (NASDAQ:TBPH), CinCor Pharma (NASDAQ:CINC), Sundial Growers (NASDAQ:SNDL), Reata Pharmaceuticals (NASDAQ:RETA) and Supernus Pharmaceuticals (NASDAQ:SUPN).
The latest price target for Innoviva (NASDAQ: INVA) was reported by Morgan Stanley on Tuesday, April 12, 2022. The analyst firm set a price target for 13.00 expecting INVA to fall to within 12 months (a possible -12.69% downside). 3 analyst firms have reported ratings in the last year.
The stock price for Innoviva (NASDAQ: INVA) is $14.89 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Innoviva.
Innoviva’s Q2 earnings are confirmed for Wednesday, July 27, 2022.
There is no upcoming split for Innoviva.
Innoviva is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.